Drugs / Bifidobacterium infantis 35624
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00135031 | Jan → Sep 2004 | irritable bowel syndrome | Procter and Gamble | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00554099 Comparator | Nov 2007 → Mar 2010 | diverticulitis | Warner Chilcott | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00510978 Comparator | Jan 2002 → Nov 2007 | Crohn disease, ulcerative colitis | University College Cork | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium infantis 35624 | “mesalamine+Bifidobacterium infantis 35624 (Align)” PMID 23426454 ↗ Aug 2013 |
| Known as | B. infantis 35624 | “362 female subjects were randomized to placebo or one of three doses of B. infantis 35624 once daily for 4 weeks.” NCT00135031 ↗ |
| Modality | Other / unclassified | “encapsulated probiotic” NCT00135031 ↗ |